Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Amgen is dealing with the threat of several fast-approaching patent expirations. The drugmaker's dividend streak is ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight – but adverse GI events were ‘common’ - The new drug may rival other weight loss medications such as Ozempic and Mounjar ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with diet and exercise alone, others find that adding weight loss medications like ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP-1 drugs, it targets a hormone that slows stomach emptying. Over 12 weeks, ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

They also have strong dividend track records. Apple and Amgen have lagged the market over the trailing-12-month period, but ...